The Evolving Process of Clinical CAR-T Manufacturing in an Academic Setting

The Evolving Process of Clinical CAR-T Manufacturing in an Academic Setting

 
A presentation with Isabelle Riviere, Director, Michael G. Harris Cell Therapy and Cell Engineering Laboratory at MSKCC

Isabelle Riviere, Director, Michael G. Harris Cell Therapy and Cell Engineering Laboratory at MSKCC delivers an immersive presentation of her team's approach to manufacturing for CAR-T clinical trials. One such trial was for adults with ALL that resulted in 85% complete responses and a five-year overall survival rate fo 50% in patients with a low disease burden.

Isabelle goes on to discuss the manufacturing issues and successes she's encountered over 12 clinical trials for various diseases, as well as the group's aim to conduct multicentre clinical trials with local, on-site manufacturing without deviations. They were, in fact, able to demonstrate comparability between the original, modular process using a Wave bioreactor with the CliniMACS Prodigy system that would be used at each trial site. A similar level of T-cell expansion and viability was able to be shown.

Watch this presentation for insight into some of the methods Isabelle and her team used to assess comparability between the modular and Prodigy platforms.